Navigation Links
Breast Cancer Patients and Families Stand Up To FDA
Date:6/24/2011

SILVER SPRING, Md., June 24, 2011 /PRNewswire/ -- Breast cancer patients and their families will rally together on Tuesday, June 28, at 7:00 am outside of the Federal Drug Administration (FDA).  At issue will be the FDA's final hearing to remove the anti-cancer drug Avastin from the approved medication list for treatment of late stage breast cancer, despite the FDA approving it in 2008 for use to treat breast cancer.

Terry Kalley, founder of the Freedom of Access to Medicines (FAMEDS), will lead the protest and then testify at the morning FDA hearing on behalf of his wife.  Following the FDA hearing, the group will make its way to Capitol Hill for congressional meetings, and wrap up the day with a media availability at 1:30 pm in 2103 Rayburn House Office Building.

"It is devastating enough to know that death will come early for these women from an incurable disease, but it is outrageous and unbelievably callous of FDA bureaucrats to compound this anguish," Kalley said.  "All we are asking for is for the federal government to stay out of our medical lives and allow my wife to continue taking this drug that is prolonging her life and the lives of many others."

At the June 28 hearing, the FDA will likely reverse its previous decision to allow Avastin to be used by breast cancer patients.  The FDA will likely cite dangerous side effects, but as Kalley pointed out, "For many breast cancer patients, including my wife, the most dangerous risk is the unavailability of Avastin."

Kalley warned that when government begins to pick winners and losers, a slippery slope towards rationing medications can happen. "Today, it's Avastin for metastatic breast cancer, tomorrow it could be the drug that your loved one needs to stay alive," he said.

He concluded with a call to action, saying "Attend our rally on the 28th, sign our online petition, and write your federal representatives and senators.  The lives of my wife and thousands of other women depend on it."

For more information on FAMEDS and the stories of breast cancer Avastin patients, go to www.fameds.org.


'/>"/>
SOURCE Freedom of Access to Medicines (FAMEDS)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... treat life-threatening diseases, today announced results for the ... 2015. --> --> ... our last quarterly call, we strategically advanced pre-clinical ... to establish the Aethlon Hemopurifier® as a leading ...
Breaking Medicine Technology:
(Date:2/5/2016)... SARASOTA, Florida (PRWEB) , ... February 05, 2016 , ... ... an event he has completed every year since it started in 2003. This year, ... attracting the attention of fellow runners and NBA team the Miami Heat. , This ...
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment and ... clinical and scientific initiatives have all marked the last 12 months at Roswell ... CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined the ...
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... your life? The answer may be at the tips of your toes. Foot massage, ... benefits as well as pure comfort and relaxation. The American Board of Multiple ...
(Date:2/5/2016)... Rafael, CA (PRWEB) , ... February 05, 2016 , ... ... with ChildLight Yoga Studio in Dover, NH to direct high-performance kids yoga training. ChildLight ... New Hampshire’s seacoast, just one hour from Boston. , ChildLight Yoga Studio founder Lisa ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... to search for and donate to Give To Cure’s campaign that is crowdfunding clinical ... lets users make and share payments through a smart device. In 2015 alone, Venmo ...
Breaking Medicine News(10 mins):